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Sequential reverse transcription and polymerssc hain reaction (RT-PCR) of the mRNA were used to invcstiptc the expression of dopamine 
rcceplors in human peripheral blood lymphocytes. The RT-PCR products contained three types of sequences. each corresponding to those of the 
D5 dop~mine receptor gene and rhc wo related pscudogencs. The lymphocyte cDN A library also contained thr clones encoding parts of the rhrcc 
genes. Binding profiles of dopaminergic ligands to the lymphocyk% wure similar to those for the native neurons1 membranes. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Dopamine receptors are integral membrane proteins 
that interact with G proteins ta transduce dopamine 
stimulation into intracellular espansas. Dopaminergic 
neurons h the human central nervous system are in- 
volved in the control of motor activity and in emotional 
and cognitive processes. Disturbances in dapaminergic 
transmission may cause psychomotor disorders, includ- 
ing Parkinson’s disease and schizophrenia, and the re- 
ceptors are primary targets for drugs used to treat the 
disorders, The human genome is known to contain 5 
genes encoding the functional dopamine receptors, 
DRDl, DRD2, DRD3, DRD4 and DRDS, and 2 genes 
highly homologous to the DRDS encading the pseu- 
dogenes [l-9], Each of the 2 pseudogenes has 5 identical 
defects in the sequence, 2 stop codons and 3 frame 
shifts, that preclude encoding of the functional receptor 
[X,9]. The expression of the dopamine receptors is well 
characterized in the brain but little work has been made 
to examine the expression in other organ tissues. 
Human peripheral lymphocytes wet@ isolated from venous blood 
obtained from healthy adult volunteers by FicolllHypaque (Pharma- 
cia LKB) gradient centrifugatiod and hypotanic lysis of crythrocytes. 
2.2. Retterse traucription and pa(werasc chain tear&n 
In this study, dopamine receptor rnRNA in human 
peripheral ymphocytes was investigated using the re- 
verse transcription-polymerase chain reaction (RT- 
PCR) and by a ligand binding assay. We report on the 
expression of the DS dopamine receptor gene (DRDS) 
and on the transcription of the 2 pseudogenes, DRiX- 
~1 and DRD5-y/2, in lymphocytes. 
Total RNA isolated from lymphocytes using the guanidium thiocy- 
anate/phenoUchloroform method [lo] was treated with SQi RNase- 
free DNase (Promcga) and then converted to first-strand cDNA cop 
ies by random priming of 1-5 pg of total RNA with Molodey murine 
leukemia virus reverse transcriptase a~ suggested by the supplier 
(Pharmacia LKB), Oligoprimcrs with corresponding sequences of 
DRDI, DRDZ, DRD3, DRD4, DRDS and@-actin gene were synthe- 
sized far RT-PCR reaction. The primer sequences used in the RT- 
PCR for the DKD5 gene are Fl; Y-TCCAGCCTGAATC- 
GAACCTAC-3’. RI; S-ACTGCAGAAAGGGACCATGCA-3’. F22; 
5’-CAATGAGCTCATCTCCC~~-~, R2; 5’-TAATGGAAT 
CCATTCGGGGTGAA-J’ and for &actin gene F: S-AAGA- 
GAGCCATCCTCACCCX-Y, R: !i’-TACATGGCI’GGCXXGT- 
TGAAJ [7.13.14]. The one-twentieth of cDNA synthesis reaction 
volume was combined in a 20 ~1 final volume for PCR amplification 
contaaining each primer and 0.2 unit Taq polymerase (Perkin-Elmet- 
Cetus). PCR was performed for 35 cycles, each cycle consisting of 
denaturation at WC (1 min), annealing at W’C (1 min) and elonga- 
tion at 72’C (1 min). The PCR-amplified products were anal@ by 
restriction fragment length polymorphism (RFLP) @g/H, BbrlI, 
Saul) and sequence analysis by rhe didcoxy termination method [I 11. 
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2.3, Prepararion of DRD5 probe 
Full length of the DRD5 was amplified from lymphocyte genomic 
DNA, and cloned into Ml3 vectorsi. After the coding sequence was 
confirmed to be identical to thal of the DRDS, insertion DNA was 
radiolabeled with [a-“P]dCTP using a random priming procedure 
VI. 
Ahhreviurianr.- RT, reverst: transcription; PCR, poiymerase chain re- 
actian; DR, dqmnhte eceptor gem; bp, base pairs. 
Aiiquors of DNA purified from a lymphocyte cDNA library (Clon- 
tech) werp subjected to PCR amplification with DRDSqtMic prim- 
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Fig. 1. (Left) Restriction map of the DRD5 and 2 pseudogenes based 
on file publi~h~i #¢Ruenzes f.7-9~, rRYghO 31£-b~ t " ra~Jn_~ t~ 
FI × RI (lane 1) was digested with Bglll, resulting in the appearance 
of additional 204 and 11 l-bp fragments (lane 2). Bbill digestion of 
264, 267-bp fragments flanked by F2 × R2 (lane 3) produced two extra 
bands (158 and 106 bp) (lane 4), and Smal digestion produced two 
extra bands (176 and 91 bp) (lane 5). Lane M: ~Z174/Hael!l. 
ers, The a.,'npfffied produc[s were efectrophoresed on 2.5% agarose 
gels, transferred to nylon membranes (Hybond N, Amersham) and 
hybridized with r,.'UP-labeled DRD5 probe. Tlae membrane was then 
washed at 65°C with 0.1 x SSC and autoradiographed. 
2.5. Dopamine binding to the t.),mphoo'te~" 
The lymphocyte preparation was diluted with sul'li¢ient Hunk's BSS 
~o tidal ~-~ ~'¢t ,,"oatKcac'd L6" x ?~' cci'?a. For saeuradon experiments, 
100/,tl aliquots of the lymphocyte suspension were incubated in trip- 
lieate w'n~ 'mcr~agm2~ con¢~ntrm)ozs of ]-~Yl)~CB~339D I')9 C))mm~), 
0.05M.9..~..~.). f¢.o 1.2Y2 • .'~.!~. . 2-2-°~. Fzt, ~¢,~.i~¢%t.l~. ~'i~{.~$ e,c~.'vi~ 
ments, assays were initiated by addition o£ 10t)~ul a]iquo~s of {he 
lymglnocy',e suspengion an~ 'medoahon "in tr!lSllcate ,,,/Kt{ inereasin_g 
concentration of dopaminc and [3HlSCH-23390 (5 nM) for 120 man 
harvester. The filters were washed with 50 mM Tris-HCl buffer (pH 
7.4), and the radioactivity was measured in a scintillation counter. 
3. RESULTS AND DISCUSSION 
Fig. I (left) shows the restriction sites for BgfH, BbiiI 
and SmaI in the regions amplified from the lymphocyte 
mRNA primed by the oligonucleotide primers F1 and 
RI (F1 × R1) and by F2 × R2. We used this restriction 
site difference to locate the eDNA encoding the DRD5 
and the pseudogenes. When a 315-bp fragment flanked 
by F1 × R1 was digested with Bg[II and subjected to 
(FIB. 1, lanes 1,2). Based on the restriction map, it was 
assumed that the lower two bands represented the 
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Fig. 2. RT-PCR products contained s~quen~s corresponding to those 
insertion relative to the DRD5 sequence. 
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Fig. 3. Co-reverse transcription-amplification of the lymphocyte 
mRNA with the 2 primer sets, F2 × R2, F × R (lane 1), and with F2 
x R2 (lane 2). The lengths of amplified products were 218 bp for 
fl-actln eDNA and 264 bp for the DRD5 eDNA. 
DRD5 or DRDS-~2 or both. Another fragment 
Y)anke6 by t:2 x R2 cou)~ be partly ~'~este~} w'nb 2~bi~l 
or ~naL indi-ca~hag the presence ormRNAs codan8 for 
cytes (b'Tg. f, lhnes 3",4",5"). S'equence analysi~ sliowed- 
and the 2 pseudogenes that corresponded to hDS~, and 
~DRDS-2 designated by other workers [7-9] (Fig. 2), 
The possibility of amplification of contaminating 
genomic DNA was eliminated in the following way. 
First, RNA samples treated by DNase were divided into 
two portions. One wa~ subjected to PCR amplification 
and the other to reverse transcription followed by PCR 
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Fig, 4, RFLP  and Southern blot analys~s of PCR-amplifi~:[ products 
from human lymphocyte eDNA library. The product flanked by FI 
× RI (lane 1) was digested wi,h tYgll[ (lane 2). The product flanked 
by F2 × R2 (lank 3) was digested with Bbill (lane ~) angt with Smal 
(lane 53, The ~vbrki~.afio~ 9at!crn w~s ~. t~h_ ls~ wJLh J~bs~ RFI,,P 
pattern in Fig. 1. 
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Fig. 5. (Left) Saturation of I~H]SCH-23390 binding to lymphocytes. Insert: Scatchard plot of the same data. (Right) Specific inhibition of 
[;H]SCH-23390 binding to the lymphocytes with dopamine. 
amplification. Only the latter could produce the frag- 
ment with the expected length of the D5 dopamine re- 
ceptor eDNA. Second, thefl-actin mRNA was reversely 
transcribed and amplified in parallel with the same reac- 
tion mixture. The fl-actin-specific primer pairs were se- 
tect'ed from two exons separated by one iacror~ic se- 
quence [13,141. As shown in Fig. 3, the/~-actin eDNA 
(2r8 bp~ but no ~ene fragment (659 bp~ was observed. 
Human ~ymphoeyte eDNA library (Clontech) was 
s~jec/tv~!y am_ISifne~h-tdmg't'ne 3ffmtea- ~,  Y'~ ~ "ik5 a-ida 
F2 × R2. The sequences of the products were shown to 
be ~deatica~ to those of the DRD5 and the pseudogeae~ 
by RFLP and hybridization analyses (Fig. 4). 
Dopaminergic antagonist [3H]SCH-23390 bound to 
the lymphocytes in a dose-dependent and saturable 
manner with a dissociation constant (Ko) of 1400 pM, 
and the binding was inhibited b), dopamine w~th ~n 
inhibitory constant (K~) of 1040 pM (Fig. 5). These 
pharmacologic profiles were similar to those of human 
and rat neuronal membranes [15,16]. The binding ca- 
pacity (B~,,,~) of [~H]SCH-23390 to the lymphocytes was 
3 fmol per nzg prote'm. This value was approximate}y 6 
times lower than that for the neural membranes of the 
dopamine receptor transiently expressed ia Cos-7 cells 
[TAX]. 
The results obtained from genetic and pharmacologi- 
cal analyses have indicated the expression of the DRD5 
and the transcription of the 2 pseudogenes in peripheral 
blood lymphocytes. We are concerned with the in vivo 
interaction of receptors and drugs in circulating blood, 
and the relation between lymphocytes and brain 
dopaminergic receptors in the course of Parkinson's 
disease. These points await further investigation. 
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